LV13400B - Subcutaneously-administered ganglioside-based vaccine compositions - Google Patents
Subcutaneously-administered ganglioside-based vaccine compositions Download PDFInfo
- Publication number
- LV13400B LV13400B LVP-05-110A LV050110A LV13400B LV 13400 B LV13400 B LV 13400B LV 050110 A LV050110 A LV 050110A LV 13400 B LV13400 B LV 13400B
- Authority
- LV
- Latvia
- Prior art keywords
- vssp
- acgm3
- group
- gangliosides
- ganglioside
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 150000002270 gangliosides Chemical class 0.000 title claims abstract description 29
- 238000007920 subcutaneous administration Methods 0.000 claims abstract description 10
- 230000001900 immune effect Effects 0.000 claims abstract description 9
- 239000000568 immunological adjuvant Substances 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003725 proteoliposome Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 abstract description 23
- 238000011282 treatment Methods 0.000 abstract description 6
- 241000588650 Neisseria meningitidis Species 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 4
- 101710116435 Outer membrane protein Proteins 0.000 abstract description 3
- 108010030416 proteoliposomes Proteins 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001173 tumoral effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20030047A CU23257A1 (es) | 2003-02-27 | 2003-02-27 | COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LV13400B true LV13400B (en) | 2006-05-20 |
Family
ID=40091613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-05-110A LV13400B (en) | 2003-02-27 | 2005-08-29 | Subcutaneously-administered ganglioside-based vaccine compositions |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US8591917B2 (el) |
| EP (1) | EP1604683B1 (el) |
| JP (1) | JP4729475B2 (el) |
| KR (1) | KR100703570B1 (el) |
| CN (1) | CN100418576C (el) |
| AR (1) | AR043377A1 (el) |
| AT (1) | ATE353668T1 (el) |
| AU (1) | AU2004216554B2 (el) |
| BR (1) | BRPI0407854B1 (el) |
| CA (1) | CA2535214C (el) |
| CL (1) | CL2004000374A1 (el) |
| CR (1) | CR7965A (el) |
| CU (1) | CU23257A1 (el) |
| CY (1) | CY1106668T1 (el) |
| DE (1) | DE602004004768T2 (el) |
| DK (1) | DK1604683T3 (el) |
| EA (1) | EA008905B1 (el) |
| EC (1) | ECSP055978A (el) |
| EG (1) | EG26446A (el) |
| ES (1) | ES2280948T3 (el) |
| GE (1) | GEP20074120B (el) |
| HK (1) | HK1087630A1 (el) |
| HR (1) | HRP20050763A2 (el) |
| IL (1) | IL170355A (el) |
| LT (1) | LT5351B (el) |
| LV (1) | LV13400B (el) |
| MY (1) | MY139811A (el) |
| NZ (1) | NZ541952A (el) |
| PE (1) | PE20040955A1 (el) |
| PT (1) | PT1604683E (el) |
| RS (1) | RS20050664A (el) |
| SI (1) | SI1604683T1 (el) |
| TN (1) | TNSN05209A1 (el) |
| TW (1) | TWI344372B (el) |
| UA (1) | UA80859C2 (el) |
| UY (1) | UY28207A1 (el) |
| WO (1) | WO2004075811A2 (el) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24534B1 (es) * | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
| CU20170173A7 (es) | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965198A (en) | 1985-12-24 | 1990-10-23 | Konica Corporation | Monoclonal antibody and method of manufacturing hybridoma producing the same |
| US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
| CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
| PE20020572A1 (es) * | 2000-12-06 | 2002-07-31 | Centro Inmunologia Molecular | Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
| EP1293212A1 (en) * | 2001-08-21 | 2003-03-19 | National Research Council Of Canada | Anti cancer vaccine comprising whole cancer cells with modified sialic acid |
-
2003
- 2003-02-27 CU CU20030047A patent/CU23257A1/es unknown
-
2004
- 2004-02-24 PE PE2004000186A patent/PE20040955A1/es not_active Application Discontinuation
- 2004-02-24 AR ARP040100571A patent/AR043377A1/es not_active Application Discontinuation
- 2004-02-25 TW TW093104808A patent/TWI344372B/zh not_active IP Right Cessation
- 2004-02-26 CL CL200400374A patent/CL2004000374A1/es unknown
- 2004-02-26 MY MYPI20040641A patent/MY139811A/en unknown
- 2004-02-27 UA UAA200508381A patent/UA80859C2/xx unknown
- 2004-02-27 US US10/547,164 patent/US8591917B2/en active Active
- 2004-02-27 KR KR1020057015531A patent/KR100703570B1/ko active IP Right Grant
- 2004-02-27 BR BRPI0407854-3A patent/BRPI0407854B1/pt not_active IP Right Cessation
- 2004-02-27 CA CA2535214A patent/CA2535214C/en not_active Expired - Lifetime
- 2004-02-27 DK DK04715239T patent/DK1604683T3/da active
- 2004-02-27 AU AU2004216554A patent/AU2004216554B2/en not_active Expired
- 2004-02-27 GE GEAP20048952A patent/GEP20074120B/en unknown
- 2004-02-27 DE DE602004004768T patent/DE602004004768T2/de not_active Expired - Lifetime
- 2004-02-27 ES ES04715239T patent/ES2280948T3/es not_active Expired - Lifetime
- 2004-02-27 EA EA200501367A patent/EA008905B1/ru not_active IP Right Cessation
- 2004-02-27 PT PT04715239T patent/PT1604683E/pt unknown
- 2004-02-27 NZ NZ541952A patent/NZ541952A/en not_active IP Right Cessation
- 2004-02-27 WO PCT/CU2004/000003 patent/WO2004075811A2/es active IP Right Grant
- 2004-02-27 EP EP04715239A patent/EP1604683B1/en not_active Expired - Lifetime
- 2004-02-27 AT AT04715239T patent/ATE353668T1/de active
- 2004-02-27 UY UY28207A patent/UY28207A1/es unknown
- 2004-02-27 CN CNB2004800052015A patent/CN100418576C/zh not_active Expired - Lifetime
- 2004-02-27 RS YUP-2005/0664A patent/RS20050664A/sr unknown
- 2004-02-27 JP JP2006501455A patent/JP4729475B2/ja not_active Expired - Lifetime
- 2004-02-27 SI SI200430262T patent/SI1604683T1/sl unknown
-
2005
- 2005-08-18 IL IL170355A patent/IL170355A/en not_active IP Right Cessation
- 2005-08-20 EG EGPCTNA2005000479A patent/EG26446A/en active
- 2005-08-24 EC EC2005005978A patent/ECSP055978A/es unknown
- 2005-08-26 TN TNP2005000209A patent/TNSN05209A1/en unknown
- 2005-08-26 CR CR7965A patent/CR7965A/es unknown
- 2005-08-29 LV LVP-05-110A patent/LV13400B/en unknown
- 2005-09-02 HR HR20050763A patent/HRP20050763A2/hr not_active Application Discontinuation
- 2005-09-21 LT LT2005087A patent/LT5351B/lt not_active IP Right Cessation
-
2006
- 2006-07-14 HK HK06107889.3A patent/HK1087630A1/xx not_active IP Right Cessation
-
2007
- 2007-04-26 CY CY20071100556T patent/CY1106668T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Silva et al. | Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responses | |
| JP4509554B2 (ja) | アルミニウムアジュバントおよびヒスチジンを含むワクチン | |
| US20220184207A1 (en) | Triterpene saponin analogues | |
| Tomai et al. | TLR7/8 agonists as vaccine adjuvants | |
| CN113412111A (zh) | 包含nfкb抑制剂和佐剂的方法和组合物 | |
| Payette et al. | History of vaccines and positioning of current trends | |
| LV13400B (en) | Subcutaneously-administered ganglioside-based vaccine compositions | |
| CA3158029A1 (en) | Tlr7/8 agonists to enhance immune responses in opioid using individuals | |
| JP2016532712A (ja) | 薬物中毒に対するワクチン組成物 | |
| KR20180040547A (ko) | 양친매성 폴리 아미노산 고분자 기반 백신 면역보조제 조성물 | |
| CN114366810A (zh) | 一种可高效诱导体液和细胞免疫的天然微生物和植物来源复合双佐剂及其制备方法和应用 | |
| Nikokar et al. | Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model | |
| KR101929973B1 (ko) | 삼당류 유도체 및 이의 보조제로서의 용도 | |
| JPS6236501B2 (el) | ||
| RU2396978C1 (ru) | Способ профилактики развития лейкоза крупного рогатого скота | |
| RU2021816C1 (ru) | Способ получения вакцины против холеры | |
| WO2022030631A1 (ja) | 組み合わせ製剤 | |
| Davies et al. | Dose-dependent adjuvant effects of Bacillus Calmette-Guerin on tumor immunity in Lewis rats | |
| RU2190424C1 (ru) | Антигенный состав чумной химической вакцины | |
| JP6689993B2 (ja) | アミロイドコンジュゲート並びにその使用及び方法 | |
| Mutwiri et al. | ALEXANDER K. ANDRIANOV | |
| Heath et al. | Shaping Modern Vaccines: Adjuvant Systems Tyrosine Using (MCT®) MicroCrystalline | |
| RU2521513C1 (ru) | Применение этония в качестве адъюванта для производства сорбированной противоящурной вакцины | |
| JP2013040152A (ja) | ワクチン効力増強添加剤およびそれを含むワクチン製剤 | |
| BG108805A (bg) | Имуностимулиращо средство |